Roger I. Gale, M.E., Chief Executive Officer
Mr. Gale is Chief Executive Officer and Chairman of the Board of Sedia Biosciences. As a co-founder, he has been with the Company since its inception in 2009. Mr. Gale also served as an Independent Director of Mechel OAO, (NYSE: MTL) from 2004 to June 2014. Previously, Mr. Gale served as Chairman of the Board of Calypte Biomedical Sciences from November 2004 until December 2008 and CEO and President until May 2008. He has also served as Executive Chairman of Wavecrest Group Enterprises Limited, a United Kingdom-based communications service provider (2001-2006) and Chairman and co-founder of End2End Wireless Limited, a UK wireless access services provider (1999-2001). He was also CEO of the Moscow–based, OPIC-guaranteed, AIG-Brunswick Millennium Fund (1995-1999) and held senior positions with the Asian Development Bank (ADB, Manila) and the International Finance Corporation (IFC, World Bank, Washington, D.C.) Mr. Gale lectured in economics at the University of New England (Australia) and Lincoln College (New Zealand). Mr. Gale holds a Master of Economics, University of New England, Australia.
Ronald W. Mink, Ph.D., President and Chief Scientific Officer
Dr. Mink has served as President and Chief Science Officer of Sedia Biosciences since 2009 and is also a co-founder. Previously, Dr. Mink served as Chief Science Officer (CSO) of Calypte Biosciences from June 2005 until December 2008 and as Director of R&D at Calypte from 2003 until 2005. He also served as a full time consultant for Calypte from 2001 to 2003. At Calypte, he introduced rapid point of care diagnostic testing technology to the company, established the oral fluid diagnostic product line, oversaw development of the BED HIV-1 Incidence EIA and expanded the company’s Aware™ line of HIV products, and launched the creation of its new Life Sciences Division. Prior to Calypte, he was Director of R&D at OraSure Technologies, Inc. (NASDAQ: OSUR). Dr. Mink holds several patents for oral fluid diagnostic tests, including the OraQuick® HIV rapid test, the first U.S. FDA approved rapid oral fluid HIV test. and other tests for oral disease pathogens. He has prior experience successfully developing and commercializing rapid assays in such companies as Eli Lilly and Co.’s diagnostic group and Carter Wallace, culminating in the commercialization of several products including First Response® One Step Pregnancy Test, First Response® 3 Minute Ovulation Test, CARDS QS® hCG, CARDS OS® Strep B and other point-of-care and OTC tests. Dr. Mink received his Ph.D. in Microbiology from the University of Illinois and B.S. and M.S. from Ohio State University.
Rick Nipper, Ph.D., Vice President, Genomics
Dr. Nipper has been serving as Vice President, Genomics, at Sedia Biosciences and CEO of Floragenex, a wholly owned subsidiary of Sedia Biosciences, since the merger of Sedia and Floragenex in October 2016. He had previously served as President of Floragenex since 2012. Prior to that role, Dr. Nipper was Vice President of Floragenex from January 2008 until October 2012. As President at Floragenex, and now as CEO of the subsidiary, he has provided operational leadership, directed R&D activities, identified business opportunities and planned expansion and growth strategies. Other responsibilities have included contract negotiations, distribution and licensing transactions, and communication with private and institutional investors. He has also held full P&L management responsibility for budget and company operational expenses. As Vice President, Dr. Nipper led growth in annual sales of next-generation sequencing services from zero-base to mid-six figures in less than 20 months. He oversaw key accounts and client projects from cradle to grave while working closely with laboratory team and off-site DNA sequencing providers to ensure continual project progression and on-time delivery of data to clients. He personally developed the company’s bioinformatics pipeline for analysis of DNA sequence data using Amazon Web Services architecture. Dr. Nipper received his Ph.D. in Molecular Biology from the University of Oregon and B.S. from Indiana University of Pennsylvania.
Jason Boone, Ph.D., Vice President, Business Development
Dr. Boone has been serving as Vice President of Business Development at Sedia since the merger of Sedia and Floragenex in October 2016. In his current role, he is overseeing the business development of both Sedia and Floragenex products in the marketplace. He previously served as Vice President of Floragenex beginning in 2012. Previously, Dr. Boone served in various roles at Floragenex, including Director of Sales from January 2010 until September 2012 and as Director of R&D from 2009 until 2010. At Floragenex, Jason spearheaded sales and business development efforts with academic and commercial life sciences groups. In addition, Dr. Boone shared operational leadership with the company President, directed R&D activities, identified business opportunities and conducted market research. He also held full sales and business development responsibility from 2012 onward and engaged with high value markets and customers to direct appropriate outcomes while negotiating, establishing, and conducting market research on new product lines and services. Dr. Boone received his Ph.D. in Molecular Biology from the University of Oregon and B.S. from The University of Vermont.
Joeciey Valero-Hansen, B.S., Director, Quality Systems
Ms. Valero-Hansen is Director of Quality Systems and has served Sedia Biosciences since 2014 with her experience developing and managing Quality System functions. Prior to joining Sedia Biosciences, Ms. Valero–Hansen functioned as the Change Configuration Manager and CAPA Coordinator for RS Medical from 2010 to 2014 where she performed stop gap analysis and overhauled the document and change control systems to bring them into compliance. She assisted in ISO and FDA audits and strove to improve and strengthen the company’s Quality System. Previous to her time with RS Medical, Ms. Valero-Hansen served in various roles with HemCon Medical Technologies from 2004-2010. As Quality System Data Coordinator, she improved and maintained the Quality System by leading the Material Review Board, CAPA, non-conformance and process deviation meetings to track and trend quality system activities. In this role, she helped to implement an FDA recommended risk based approach to non-conformances and CAPA as well as significantly decreased the use of planned deviations. Previous to that, Ms. Valero-Hansen served as an Auditor, in addition to being a Quality Control Technician. In this dual role, she monitored the company’s critical suppliers and internal manufacturing processes for continued compliance and assisted in ISO and FDA audits. Additionally, she served on the quality system compliance committee to rewrite and implement Standard Operating Procedures for compliance to and to achieve ISO 13485 certification. Ms. Valero-Hansen received her B.S. in Molecular and Cellular Biology from California State University, Fresno.